Overview of Bonair

Property	Description
Active ingredient	Salbutamol (Albuterol)
Form	Solution for inhalation / Metered-Dose Inhaler (MDI)
Pharmacological class	Short-Acting beta2-Adrenergic Receptor Agonist (SABA)
General purpose	Rapid relief from bronchospasm
Origin	Synthetic compound

Core Identity and Pharmacological Classification

Bonair is a prescription-only medication whose single active component is the synthetic compound Salbutamol, which is internationally recognized as Albuterol. This medicine is a beta2-Adrenergic Agonist. This classification places it within the group of Short-Acting beta2-Agonists (SABAs), which are recognized for their ability to provide swift therapeutic action in the respiratory tract. Salbutamol, often supplied as the sulfate salt, functions as a selective agent that targets the muscles lining the bronchial tubes.

General Purpose as a Bronchodilator

The primary purpose of Bonair is to function as a bronchodilator, providing rapid, temporary relief from the acute tightening of the air passages in the lungs, known as bronchospasm. The medication is used for swiftly reversing this acute constriction, a function required in scenarios involving sudden, temporary breathing difficulty. By causing smooth muscle relaxation in the bronchial walls, Bonair mitigates immediate respiratory distress, serving as a fast-acting, acute-relief treatment.

Composition and Inhalation Formats

Bonair is a single-ingredient product whose therapeutic effects are delivered by the targeted inhalation route. This route ensures the active substance, Salbutamol, reaches the lungs quickly, leading to a rapid onset of relief. The medication is typically manufactured as a solution for inhalation (designed for use with a nebuliser) or as an aerosol within a pressurized metered-dose inhaler (MDI). These formats ensure the delivery of the Salbutamol sulfate to the bronchial tubes, maximizing its local effect while minimizing the time needed to counter acute bronchospasm.

Regulatory References

What side effects are possible with Bonair?

Possible Side Effects and Safety Information

Official regulatory documents classify the adverse reactions of Bonair (Salbutamol) based on frequency and the body system affected. Most observed effects are characteristic of a sympathomimetic agent, involving the cardiovascular and nervous systems.

Commonly Documented Adverse Reactions

Reactions classified as common in official labeling include tremor, headache, tachycardia (increased heart rate), and palpitations. Other common effects, often related to the inhalation route, include throat irritation and cough. These effects are generally mild and, according to regulatory sources, may lessen or disappear with continued use.

Serious Adverse Reactions and Warnings

The label documents specific, rare, but serious adverse events. Paradoxical bronchospasm, where breathing suddenly worsens after administration, is a life-threatening reaction that mandates immediate discontinuation. Hypersensitivity reactions, such as anaphylaxis, angioedema, and severe bronchospasm, are also documented.

Clinically significant cardiovascular effects (e.g., changes in pulse rate, blood pressure, or rare occurrences of myocardial ischemia) are officially noted, leading to a caution that excessive use may be fatal and should be avoided.

Safety Considerations for Specific Populations

Regulatory warnings advise caution when using this medicine in patients with pre-existing conditions, including cardiovascular disorders (such as hypertension or coronary insufficiency), convulsive disorders, diabetes mellitus, and hyperthyroidism. Use during pregnancy or lactation is generally restricted to situations where the potential benefit is judged to outweigh possible risks. Additionally, the drug has the potential to cause hypokalemia (low serum potassium), which is a key safety point, particularly in patients receiving concurrent treatment with diuretics or steroids, and may require monitoring.

Overdose and Emergency Response

The official regulatory profile for Bonair (Salbutamol) overdose is defined by the exaggeration of its known pharmacological effects, necessitating immediate emergency care.

Documented Manifestations and Severe Outcomes

Overdosage is officially associated with transient beta2-agonist pharmacologically mediated events. Documented clinical signs typically include tachycardia, palpitations, and physical effects such as tremor, restlessness, and headache.

Potential severe systemic outcomes listed in regulatory documents include serious metabolic and electrolyte disturbances, specifically hypokalaemia (low serum potassium) and lactic acidosis, which may lead to metabolic acidosis. Life-threatening complications documented are severe cardiac arrhythmias and, rarely, myocardial ischemia or seizures.

Emergency Actions Required

Due to the risk of severe cardiovascular and metabolic instability, regulators mandate that any suspected overdose requires immediate medical attention or contact with emergency services.

Management is symptomatic and supportive. There is generally no specific antidote listed in official labeling. Medical professionals will require continuous monitoring of vital signs and laboratory parameters, particularly serum potassium levels, until stability is achieved. Special caution is advised for patients with acute severe asthma, as the adverse effects of overdose may be compounded by co-existing conditions.

Therapeutic Uses of Bonair

What Bonair Treats: Main Uses and Benefits

Bonair (Salbutamol) is commonly used to help provide symptomatic assistance across domains involving symptoms related to heightened physiological activity, focusing on episodes of patient distress related to airway restriction.

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, and is considered relevant for addressing conditions characterized by periods of heightened symptoms. Its uses are relevant for the management of Asthma, Chronic Obstructive Pulmonary Disease (COPD), and related reversible airway obstruction. The therapeutic benefit is centered on easing symptom clusters that may become intense or disruptive, such as wheezing, chest tightness, and difficulty breathing.

The medication plays a role in managing both sudden, unexpected acute exacerbations and is also applied in a prophylactic manner, for instance, before exposure to predictable triggers like exercise or cold air, to manage the risk of symptom onset. This supportive assistance may help patients cope more steadily with difficult episodes.

“Bonair is relevant when supportive symptom management is appropriate, particularly during phases when symptoms become more noticeable.”

Quick Fact: Supportive Management for Acute Bronchospasm

Regulatory References

NIH MedlinePlus overview on Albuterol

Eligibility and Restrictions for Use

Official Eligibility Profile: Bonair (Salbutamol)

Regulatory authorities define the population for Bonair use based on age, physiological status, and pre-existing medical conditions. All information below is derived strictly from official regulatory labeling.

Eligibility Status Summary

Category	Official Regulatory Status
Populations Contraindicated	Patients with known hypersensitivity to Salbutamol or any component of the formulation. Must not be used for threatened abortion or uncomplicated premature labour (non-intravenous forms).
Age-Related Rules	Approved for use in adults and children aged 4 years and older. Safety and effectiveness have not been established in children under 4 years of age (MDI/HFA formulations).
Conditional Use (Caution Required)	Use must be approached with caution in patients with severe cardiovascular disorders (including coronary insufficiency, arrhythmias, and hypertension), thyrotoxicosis (hyperthyroidism), diabetes mellitus, or convulsive disorders.
Pregnancy and Lactation	Pregnancy use is restricted to when the expected maternal benefit outweighs potential fetal risk. Lactation is generally not recommended, as Salbutamol is likely secreted in breast milk.

Eligibility Severity Classification

Regulatory documents classify non-eligibility into: Contraindicated (absolute prohibition), Caution (conditional use with risk assessment for certain comorbidities), and Use Not Established (absence of sufficient data in specific age groups).

What should I know about interactions with other medicines?

The official regulatory documentation for Bonair (Salbutamol) establishes specific interaction patterns based primarily on two pharmacological outcomes: antagonism and the potentiation of systemic effects. These interactions necessitate constraints on co-administration.

Formal Prohibitions and Restrictions

Interacting Substance/Class	Official Regulatory Statement
Non-selective beta-blockers	Co-administration is generally not prescribed as these agents may functionally block the intended pulmonary effect of Bonair and may produce severe bronchospasm.
Other Sympathomimetic Agents	Concomitant use is not recommended due to the potential for deleterious cardiovascular effects.

Pharmacodynamic and Timing Constraints

Other interactions carry warnings based on the potential for systemic potentiation. Use with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs) requires extreme caution because the action of Bonair on the vascular system may be potentiated. This restriction extends to use within two weeks of discontinuing such agents. Drugs that can cause hypokalemia, such as Non-potassium-sparing Diuretics, Xanthine Derivatives, and Corticosteroids, may have their hypokalemic effect potentiated. Co-administration with Digoxin is documented to cause a decrease in serum Digoxin levels. Furthermore, Halogenated Anaesthetic Agents require caution due to the risk of severe dysrhythmia, leading to a regulatory constraint that Bonair should not be used for at least six hours prior to anaesthesia. The risk of adverse reactions is noted as possibly greater in patients with impaired renal function.

Mechanism of Action

Bonair is an oral prodrug, bambuterol hydrochloride, which undergoes enzymatic hydrolysis primarily by butyrylcholinesterase, predominantly in the liver. This metabolic conversion yields its active form, terbutaline. Terbutaline functions as a selective agonist of beta-2 adrenergic receptors, which are localized on the smooth muscle cells of the bronchial airways.

Binding of terbutaline to the beta-2 receptor activates adenylyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). The resulting increase in intracellular cAMP concentration leads to the activation of protein kinase A (PKA). PKA subsequently phosphorylates target proteins, causing the downstream inhibition of myosin light-chain kinase (MLCK). Since MLCK activity is essential for actin-myosin interaction and subsequent muscle contraction, its inhibition induces smooth muscle relaxation, resulting in systemic bronchodilation and improved airflow.

Dosage and Administration Information

How Bonair is Used: Administration Overview

Bonair (Salbutamol/Albuterol) is administered via oral inhalation using either a pressurized metered-dose inhaler (MDI) or an approved nebulizer system. The solution must not be swallowed or injected. Its use is based on symptomatic need, making the pattern primarily as-needed (PRN).

Typical Dosing and Frequency

The typical adult dose for symptom relief with the MDI is 2 inhalations (180 mcg albuterol base), which may be repeated every 4 to 6 hours as required. For preventative use before exposure to triggers, such as exercise, the 2 inhalation dose is taken 15 to 30 minutes prior to the activity. The maximum MDI dose is 8 inhalations (720 mcg) in any 24 hour period.

Nebulizer solution is typically dosed at 2.5 mg to 5 mg and may be repeated up to four times daily. An increased requirement for more frequent dosing signals a loss of therapeutic control and necessitates immediate medical re-evaluation.

Procedural and Age-Specific Rules

Proper administration requires device maintenance. The MDI must be primed with test sprays if it has been unused for longer than two weeks, and the actuator must be cleaned at least once per week with water and fully air-dried. For pediatric patients aged 4 years and older, the MDI and nebulizer regimens are the same as the adult dose. While concentrated nebulizer solutions must be diluted with sterile normal saline, unit-dose vials are generally used undiluted.

Recent Clinical Evidence

Bonair: Recent Clinical Evidence

Mechanism of Action Studies

Researchers hypothesized a potential mechanism involving a specific neuroreceptor pathway associated with movement control. Studies evaluated the compound's interaction with this pathway in animal models and in-vitro human cell lines. Findings suggested modulation of a pathway.

Clinical Trial Data (Phase 2 and 3)

The treatment option that has been examined in clinical trials was studied in patients with mild to moderate disease.

Motor Symptom Exploration: In Phase 3 Randomized Controlled Trials (RCTs), studies evaluated whether the compound affected motor symptoms. Trial data suggested a change in the primary motor function scale score compared to placebo over a 12-week period.
Secondary Outcomes: The study also examined the effects on pain and fatigue. Changes in tremor frequency were also noted.
Long-term Observation: A one-year open-label extension study followed participants from the initial RCTs. This longer-term observation explored effects on various health measures and the maintenance of observed changes.

Pharmacokinetic and Drug-Interaction Studies

Pharmacokinetic studies examined how the compound is absorbed, distributed, metabolized, and excreted by the body.

Combination Formulation Analysis

The combination formulation was designed to explore effects on absorption kinetics compared to the single compound alone. Studies assessed whether the inclusion of an absorption enhancer affected how quickly and at what level the compound appeared in the bloodstream.

Research Gaps and Future Direction

Evidence remains limited on the long-term effects beyond two years. Further research is needed to explore direct comparative effects against other current therapies. It is not yet clear whether treatment with this compound affects disease progression.

Key Studies & References Long-Term Safety and Durability of Response to Bonair: Results from a One-Year Open-Label Extension Study

Frequently Asked Questions (FAQ)

Common questions about Bonair (FAQ)

Q: How quickly does Bonair usually start working?

Official documents classify Bonair as a Short-Acting beta2-Adrenergic Receptor Agonist (SABA), which is designated for providing rapid relief from acute symptoms. Due to its classification as a SABA, the medication is intended for a rapid onset of effect after inhalation, consistent with its designation as a quick-relief treatment.

Q: Does Bonair need to be taken long-term?

According to official product information, this medicine is typically designated as a quick-relief treatment taken as needed for acute symptoms. Consistent, daily use may be considered a marker that a person's underlying condition requires medical re-assessment, as regulatory guidance defines the medicine primarily for acute, as-needed relief.

Q: Is Bonair the same kind of drug as [similar-sounding drug]?

Bonair is a Short-Acting beta2-Adrenergic Receptor Agonist (SABA). It is classified in the same broad pharmacological group as other medicines that act quickly to relax the bronchial muscles. The official information describes its function as providing rapid relief from bronchospasm.

Q: Why did my doctor prescribe Bonair instead of another option?

The medicine’s official role is limited to providing rapid, temporary relief from bronchospasm (the tightening of the air passages). The specific selection of treatment options is a clinical decision made by a healthcare provider.

Q: Are there common side effects I should know about before starting Bonair?

Regulatory documents commonly list side effects such as tremor (shakiness), headache, increased heart rate (tachycardia), and palpitations. Other frequently documented effects related to the inhalation route include throat irritation and cough.

Q: Is a headache a common side effect when first taking Bonair?

Headache is officially listed as a commonly documented adverse reaction to this medicine. Regulatory sources note that for many people, commonly documented effects may diminish with continued use.

Q: Can Bonair make me feel tired or drowsy?

Official labeling for the active ingredient, Salbutamol, includes general feelings of discomfort or illness (malaise) and tiredness (fatigue) among the possible side effects.

Q: Can Bonair cause sleep problems or insomnia?

Difficulty falling asleep (insomnia) is documented as a possible adverse reaction associated with this medication, according to official regulatory information.

Q: Is it true that Bonair helps with [vague symptom]?

The primary approved use of this medicine is for bronchospasm relief. Clinical trials have also included the exploration of effects on other factors, such as pain, fatigue, and motor symptoms, which were evaluated as secondary outcome measures.

Q: What happens if I stop taking Bonair suddenly?

Bonair is a quick-relief medicine used for acute symptoms. As a result, sudden discontinuation may lead to the return or worsening of underlying breathing difficulties. The use of this medicine should only be stopped as determined by a healthcare provider.

Q: What should I do if I forget to take a dose of Bonair?

For a missed dose (if the medicine is taken on a regular basis), the official procedure is to take it as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped. Do not take a double dose to make up for a missed dose.

Q: What if I take two doses of Bonair too close together?

Taking doses too frequently risks exceeding the maximum amount of medicine permitted by official labeling. Regulatory warnings advise against excessive use, which can lead to a greater risk of serious side effects, particularly those affecting the heart.

Q: Does Bonair have any restrictions related to driving or operating machinery?

The official adverse reaction list includes effects such as tremor and headache or dizziness. These documented effects may affect the ability to perform tasks that require focus and coordination.

Q: Is Bonair addictive or habit-forming?

This medicine is not classified as addictive or a controlled substance by regulatory authorities. However, the official label warns against excessive use, which can lead to reduced effectiveness and worsening control of the underlying condition.

Q: Are there different strengths of Bonair available?

The active ingredient is formulated for inhalation in a few standard strengths, depending on the device. These include the pressurized metered-dose inhaler and the solution designed for use in a nebulizer.

Q: Why does Bonair sometimes cause nausea?

Regulatory information documents that nausea is included among the documented adverse reactions for the active ingredient, Salbutamol.

Q: Has Bonair been studied in a lot of people?

The active ingredient has been examined in Phase 2 and Phase 3 Randomized Controlled Trials (RCTs). The clinical development program for one formulation treated a number of subjects that exceeded 1,000 to gather data for regulatory review.

Q: Where can I find official information about the research on Bonair?

Official research summaries and regulatory decisions are available on the websites of government drug authorities. You can typically find detailed documentation from agencies such as the FDA (Food and Drug Administration) and the NIH (National Institutes of Health).

Q: Does official research support using Bonair for conditions other than [main condition]?

The primary approved purpose of the medicine is for bronchospasm relief. While clinical trials have also included the exploration of effects on other factors, such as pain, fatigue, and motor symptoms, these were evaluated as secondary outcome measures.

Q: Is it normal to feel no change after starting Bonair?

Bonair is classified as a rapid-acting medicine, intended to relieve acute symptoms quickly. Regulatory guidance indicates that an increased requirement for more frequent dosing is often considered a sign of a loss of therapeutic control for the underlying condition.

Q: Is there a generic version of Bonair available?

Yes, the active component of Bonair is Salbutamol (also known as Albuterol). Generic versions of the inhalation solution and metered-dose inhaler containing this active ingredient are widely available.

Q: What's the difference between the brand name and the generic name of Bonair?

The brand name is Bonair. The active component is the internationally recognized generic name, Salbutamol, which is also commonly referred to as Albuterol in the United States.

Q: Does Bonair lose effectiveness over time?

Regulatory guidance indicates that an increased need for more frequent dosing may signal a loss of therapeutic control for the underlying condition. An increase in the required dose frequency is often considered a need for medical re-assessment of the underlying condition.

Q: Are there any known withdrawal symptoms if Bonair is stopped?

When a quick-relief medicine is stopped, the return of the symptoms it was treating can occur. The primary risk of stopping this medication is the sudden return or worsening of underlying breathing difficulties.

Q: Does Bonair affect blood pressure?

Regulatory warnings note that Bonair, like other beta2-adrenergic agonists, can produce changes in blood pressure and pulse rate. Due to these potential effects, use with caution is advised for patients with existing cardiovascular disorders.

How should Bonair be stored and disposed of?

The official labeling for Bonair (Salbutamol/Albuterol) specifies strict environmental and container requirements to maintain product integrity.

Storage Conditions

Bonair must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must not be frozen and requires protection from direct light and excessive heat. Nebuliser solution vials must remain in their original foil pouch until use. Once an inhalation solution vial is opened, any unused portion must be discarded immediately. Multi-dose inhalers have a limited shelf-life after the foil pouch is first opened, which may be six to thirteen months depending on the formulation.

Disposal and Safety

The medicine must be kept out of the reach of children. Unused or expired Bonair should be disposed of through a medication take-back program where available, following governmental guidelines. Pressurized MDI canisters should not be punctured or thrown into a fire.

Bonair